PFE slips as report flags 2026 U.S. drug price hikes
NEW YORK, January 1, 2026, 20:51 ET — Market closed
- Pfizer shares last traded at $24.90, down 0.4% from the previous close.
- A Reuters report said Pfizer plans list-price increases on around 80 medicines for 2026, including a 15% hike for its COVID-19 vaccine.
- Investors are watching for more early-January pricing disclosures, the Jan. 9 U.S. jobs report and Pfizer’s expected Feb. 3 earnings date.
Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its…
